Levetiracetam Ucb

Levetiracetam, the active ingredient in Levetiracetam Ucb, is an anticonvulsant presented as an intravenous solution for intravenous use. It is employed to treat various seizure types in patients with epilepsy, including partial, generalized tonic‑clonic, myoclonic seizures and status epilepticus. GNH USA supplies Levetiracetam Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an antiepileptic drug that modulates neuronal excitability to control seizure activity.

Partial seizures: helps control focal seizure activity in patients with epilepsy. Generalized tonic‑clonic seizures: reduces the frequency and severity of bilateral convulsive episodes. Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with epilepsy. Status epilepticus: provides rapid seizure control when conventional therapy is insufficient.

Levetiracetam may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: sensation of light‑headedness or loss of balance. - Somnolence: increased sleepiness during the day. - Headache: mild to moderate head pain. - Irritability: mood changes including agitation. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or Stevens‑Johnson syndrome. - Psychiatric disturbances: depression, aggression, or suicidal thoughts. - Thrombocytopenia: markedly reduced platelet count leading to bleeding risk. - Rhabdomyolysis: muscle breakdown that can cause kidney injury.

When using Levetiracetam intravenous solution, clinicians should consider several safety measures.

Renal impairment: adjust dosing or monitor plasma levels in patients with reduced kidney function. Pregnancy: risk category unknown; prescribe only if potential benefit justifies potential fetal risk. Psychiatric history: monitor for mood changes, depression, or suicidal ideation. Concomitant CNS depressants: observe for additive sedation or respiratory depression. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam has a relatively low interaction profile, but certain drug combinations require caution.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): may significantly reduce levetiracetam plasma concentrations. - Live vaccines: concurrent use may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - Sedative CNS depressants (benzodiazepines, opioids): may increase sedation and respiratory depression. - Alcohol: can enhance central nervous system depression. - Renally cleared drugs: monitor renal function to avoid accumulation of co‑administered agents.